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Abstract
Purpose Ureteral stents are frequently associated with
side eVects. Most patients suVer from storage lower urinary
tract symptoms (LUTS). Storage LUTS are commonly
attributed to the irritation of the trigone, smooth muscle
spasm or a combination of factors. The relationship
between microbial ureteral stent colonization (MUSC) and
de novo or worsening storage LUTS has not been investi-
gated yet.
Methods Five hundred ninety-one polyurethane ureteral
stents from 275 male and 153 female patients were
prospectively evaluated. The removed stents were soni-
cated to dislodge adherent microorganisms. Urine Xow
cytometry was performed to detect pyuria. A standardized
urinary symptom questionnaire was given to all patients.
Results Thirty-Wve per cent of male and 28% of female
cases showed de novo or worsened storage LUTS. MUSC
was more common in patients with storage LUTS com-
pared to patients without storage LUTS (men: 26 vs. 13%,
respectively, P < 0.05; women: 63 vs. 48%, respectively,
P = 0.13). Pyuria was signiWcantly more common in
patients with storage LUTS compared to patients without
storage LUTS (men: 55 vs. 40%, respectively, P < 0.05;
women: 70 vs. 45%, respectively, P < 0.05). No signiWcant
correlation was observed between the detected genera of
microorganisms and storage LUTS.
Conclusions Our data show a signiWcant association
between MUSC- and stent-related de novo experienced or
worsened storage LUTS in men. The incidence of MUSC is
most common in both female and male patients with stor-
age LUTS and accompanying pyuria. In these patients, a
combination of antibiotics and anti-inXammatory drugs
may be regarded as treatment option.
Keywords BioWlm · Neurogenic inXammation · 
Microbial colonization · Pyuria · Storage lower · 
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Introduction
Ureteral stents are widely used to maintain upper urinary
tract function. However, many patients experience
unpleasant urinary symptoms, Xank pain and haematuria.
The most commonly reported stent-associated symptoms
include frequency, nocturia, urgency and urgency urinary
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542 World J Urol (2013) 31:541–546incontinence [1–3], summarized as ‘storage lower urinary
tract symptoms’ (storage LUTS). The pathophysiology of
stent-related storage LUTS is poorly understood. Multiple
theories have been suggested including mechanical irrita-
tion of the bladder, exacerbation of pre-existing detrusor
overactivity and smooth muscle spasms of the distal ure-
ter. Similar to other medical implants, ureteral stents bear
an intrinsic risk of microbial colonization and consecutive
bioWlm formation. The relationship between microbial
ureteral stent colonization (MUSC) and storage LUTS has
not yet been investigated. We have recently shown that
sonication of ureteral stents is a valuable means for the
detection of MUSC [4, 5] and, therefore, allows for the
study of its eVects on patients. We report here the results
of a prospective clinical trial using sonication in the
detection of MUSC. Data on clinical signs and symptoms
as well as laboratory urine analyses were evaluated in an
attempt to correlate these results with MUSC.
Methods
Study population
All patients who had their stent(s) removed during the
study period (March 2008–July 2010) for any clinical rea-
son were eligible for the study. After providing informed
consent, patients were followed using a standardized case
report form. The study was approved by the local ethics
committee. Exclusion criteria included renal transplant
(n = 93), refusal of consent (n = 5), bilateral stents
(n = 30), missing questionnaire (n = 1), stent migration
into the bladder (n = 1), missing urine or urine Xow
cytometry results (n = 12) and urine sampling via an ileal
conduit or an indwelling transurethral catheter (n = 11).
Patient questionnaire
All patients were asked to Wll in a standardized question-
naire (‘Appendix in Electronic supplementary material’) at
the time of their stent removal. The formally non-validated
questionnaire was designed with the objective to assess the
prevalence of de novo experienced or worsened storage
LUTS (Urinary frequency, urgency, nocturia and urgency
urinary incontinence) and pain (suprapubic pain, Xank pain
and Xank pain during voiding) in the period of stenting. It
consists of eight questions. The alternatives of the ques-
tions were dichotomous, having only the options yes or no.
If one or more of the questions a–d was answered with
‘yes’, the patient was allocated to the storage LUTS group.
Patients were interviewed, when they were unable to Wll in
the form or answers were unclear. Data were transferred to
a spread sheet (Microsoft OYce Excel 2010) and cross-
checked before being exporting to statistical analysis
software.
Urine analysis
Urine samples were obtained prior to device removal and
analysed by conventional culture methods and the Sysmex
UF1000i (TOA Medical Electronics, Kobe, Japan). This
device is a fully automated Xuorescence Xow cytometer
able to classify and count cells and formed particles in
native uncentrifuged urine samples [8].
Ureteral stent sonication
Ureteral stents were removed under aseptic conditions,
divided into small parts, placed in sterile tubes and pro-
cessed by the microbiology laboratory within 6 h. Stent
colonization was detected by sonication as described previ-
ously [4]. Microorganisms were enumerated and classiWed
by routine microbiologic techniques.
Statistical analysis
Analyses were performed using SPSS version 17 software
(SPSS, Inc., Chicago, IL). McNemar’s test was applied as
appropriate. A P value of <0.05 was considered to indicate
statistical signiWcance. All tests were two-sided.
DeWnitions
Microbial ureteral stent colonization (MUSC)
Growth of ¸102 CFU/mL in sonicate-Xuid culture (SFC).
Because no validated cut-oV value for MUSC diagnosed
by sonication exists, a threshold of ¸102 CFU/mL was
chosen according to recommendations for intravascular
catheters [6].
Ureteral stent contamination
Growth of <102 CFU/mL and mixed gram-positive Xora in
SFC.
Positive urine culture (PUC) and urine contamination
Urine sample collection, quantitation (CFU/mL) and organ-
ism isolation and enumeration were performed as described
by Wilson et al. [7].
Pyuria
Presence of ¸40 leucocytes per microlitre of urine detected
by the urine Xow cytometer Sysmex UF1000i [8].123
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Urinary frequency, urgency, nocturia and urge incontinence
[9].
Unique ureteral stent insertion
Stents obtained from patients undergoing singular stenting
or the Wrst stent removed from patients with continuous
stenting.
Continuous ureteral stenting
Stents obtained from patients with continuous stenting with
the exception of the Wrst-placed stent.
Results
Five hundred ninety-one (591) polyurethane stents from
275 male and 153 female patients were removed during the
study period. One hundred Wfty-three (153) devices were
excluded based on the outlined exclusion criteria. Complete
data for 438 stents from 197 male and 118 female patients
were analysed (Table 1).
Sonicate-Xuid culture
Sonicate-Xuid culture (SFC) detected MUSC in 31%. Fifty-
three discordant observational pairs were positive with son-
ication only, compared to 13 positives with urine culture
only. All negative controls (n = 8) were negative in SFC.
Stents obtained from female patients showed signiWcantly
higher proportion of MUSC (52%) than stents obtained
from men (18%, P < 0.05).
Urine culture
The relationship between positive urine culture, SFC and
pyuria and the association with de novo or worsened stor-
age LUTS are demonstrated in Table 2. In addition, we
observed a signiWcantly higher proportion of asymptomatic
bacteriuria (ASB) in female compared with male cases (20
vs. 6%, P < 0.05).
Male patients
On the day of stent removal, 35% of male cases showed de
novo or worsened storage LUTS. MUSC was more common
in patients with storage LUTS (26%) than in patients without
storage LUTS (13%, P < 0.05). Furthermore, pyuria was sig-
niWcantly more common in patients with storage LUTS
(55%) than in patients without storage LUTS (40%,
P < 0.05). Patients with storage LUTS and accompanying
pyuria showed signiWcantly more MUSC (36%) than patients
with storage LUTS without pyuria (14%, P < 0.05). Patients
Table 1 Study population
MUSC microbial ureteral stent colonization; LUTS lower urinary tract
symptoms
Variables N Storage LUTS No storage LUTS
Study group 438 (100%) 142 (32%) 296 (68%)
Unique ureteral 
stent insertion
303 (69%) 96 (32%) 207 (68%)
Continuous 
stent insertion
135 (31%) 46 (34%) 89 (66%)
Sex
Male 274 (63%) 96 (35%) 178 (65%)
Female 164 (37%) 46 (28%) 118 (72%)
Age
Up to 50 years 168 (39%) 54 (32%) 114 (68%)
>50 years 270 (61%) 88 (33%) 182 (67%)
Indwelling time
<30 days 202 (46%) 64 (32%) 138 (68%)
¸30 days 236 (54%) 78 (33%) 158 (67%)
Sonication
MUSC 135 (31%) 54 (40%) 81 (60%)
No MUSC 303 (69%) 88 (29%) 215 (71%)
Urine culture
Positive 68 (16%) 33 (49%) 35 (51%)
Negative 370 (84%) 109 (29%) 261 (71%)
Urine Xow cytometry
Pyuria 209 (48%) 85 (41%) 124 (59%)
No Pyuria 229 (52%) 57 (25%) 172 (75%)
Indication
Ureterorenoscopy 162 (37%) 58 (36%) 104 (64%)
Obstructive 
uropathy
141 (32%) 48 (34%) 93 (66%)
Malignancy 27 (6%) 8 (30%) 19 (70%)
Other 108 (25%) 28 (26%) 80 (64%)
Table 2 Relationship between positive urine culture sonicated Xuid
culture, pyuria and de novo experienced or worsened storage LUTS
MUSC microbial ureteral stent colonization; PUC positive urine cul-
ture; LUTS lower urinary tract symptoms
Storage LUTS No storage LUTS
MUSC 
(%)
PUC 
(%)
P value MUSC 
(%)
PUC 
(%)
P value
Men
Pyuria 36 23 <0.05 20 11 <0.05
No pyuria 14 7 0.2482 9 3 <0.05
Women
Pyuria 69 47 <0.05 58 36 <0.05
No pyuria 50 21 0.1336 40 8 <0.05123
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more MUSC (20%) than patients without storage LUTS and
missing pyuria (9%, P = 0.08).
Female patients
On the day of stent removal, 28% of female cases showed
de novo or worsened storage LUTS. No statistical signiW-
cance in the incidence of MUSC could be detected when
comparing female patients with storage LUTS (63%) and
without storage LUTS (48%, P = 0.13). Pyuria was signiW-
cantly more frequent in patients presenting with storage
LUTS (70%) than in patients without storage LUTS (45%,
P < 0.05). Patients with storage LUTS and accompanying
pyuria showed more MUSC (69%) than patients with stor-
age LUTS and no pyuria (50%, P = 0.38). Similarly,
patients without storage LUTS and accompanying pyuria
showed more MUSC (58%) than patients without storage
LUTS and no pyuria (40%, P = 0.07).
Microorganisms detected by sonication
Details of the detected microorganisms and their associa-
tion with de novo or worsened storage LUTS are shown in
Tables 3 and 4. No signiWcant correlations between the
detected genera of microorganisms and storage LUTS were
observed.
Discussion
Indwelling ureteral stents frequently result in major patient
morbidity. Studies examining stent composition, size,
length, design and position with the objective to improve
patient quality of life are contradictory [10–13]. Patients
most commonly report symptoms of overactive bladder
including urinary frequency, urgency, nocturia and urgency
urinary incontinence [1–3]. These symptoms are commonly
referred to as storage LUTS [9]. Storage LUTS are gener-
ally attributed to smooth muscle spasm and local irritation
of the trigone by the distal coil of the stent [3, 14–17].
The role of MUSC in the pathogenesis of stent-related
storage LUTS has not yet been studied. MUSC and consec-
utive bioWlm development is a multistep process [18, 19]
starting with the formation of a conditioning Wlm consisting
of host proteins, electrolytes and other substances [20]. The
Wnal bioWlm is formed by materials oVered by the environ-
ment and extracellular polymeric substances produced by
pathogens. After a bioWlm is formed, microorganisms
detach as a result of cell growth and division or the removal
of bioWlm aggregates which contain masses of cells. Uro-
thelial cells sense bioWlm pathogens by diverse receptors
and react by producing substances (e.g. nitric oxide, cath-
elicidin and -defensin-2) toxic to invaders [21–23]. In
addition, they produce a number of chemokines and proin-
Xammatory cytokines. Cytokine-mediated upregulation of
adhesion molecules and cytokine receptors facilitate the
process of immune cell migration. Leucocytes accumulate
in the urine and urothelium to eliminate bacteria. However,
their released toxic contents damage not only pathogens,
but also the surrounding tissue. Local inXammation leads to
stimulation and activation of aVerent nerves, resulting in
storage LUTS. In addition, bacterial toxins (e.g.,  LPS)
were recognized by the immune system and initiate local
Table 3 Microorganisms detected by sonication in male cases
LUTS lower urinary tract symptoms
a Coagulase-negative staphylococci spp
b Escherichia coli (n = 6), Serratia marcescens (n = 2), Proteus spp.
(n = 1), Klebsiella pneumoniae (n = 1)
c Kocuria kristinae (n = 1), Staphylococcus aureus (n = 2), Pseudo-
monas aeruginosa (n = 2), Moraxella catarrhalis (n = 1)
Male cases N Storage 
LUTS
No storage 
LUTS
No. of microorganisms 64 (100%) 36 (51%) 28 (49%)
CoNSa 21 (33%) 12 (57%) 9 (43%)
Enterococcus spp. 11 (17%) 4 (36%) 7 (64%)
Enterobacteriaceaeb 10 (16%) 7 (70%) 3 (30%)
Candida spp. 9 (14%) 6 (67%) 3 (33%)
Streptococcus spp. 4 (6%) 3 (75%) 1 (25%)
Corynebacterium spp. 3 (5%) 1 (33%) 2 (67%)
Otherc 6 (9%) 3 (50%) 3 (50%)
Table 4 Microorganisms detected by sonication in female cases
LUTS lower urinary tract symptoms
a Coagulase-negative staphylococci spp
b Escherichia coli (n = 22), Proteus spp. (n = 3), Klebsiella pneumo-
niae (n = 1), Citrobacter freundii (n = 1)
c Kocuria rosea (n = 5), Kocuria kristinae (n = 2), Staphylococcus au-
reus (n = 1), Pseudomonas aeruginosa (n = 1), Erysipelothrix rhusiop-
athiae (n = 1), Dermacoccus nishinomiyaensis (n = 1), Aerococcus
urinae (n = 1)
Female cases N Storage 
LUTS
No storage 
LUTS
No. of microorganisms 136 (100%) 50 (37%) 86 (63%)
CoNSa 13 (10%) 4 (31%) 9 (69%)
Enterococcus spp. 23 (17%) 9 (39%) 14 (61%)
Enterobacteriaceaeb 27 (20%) 14 (52%) 13 (48%)
Candida spp. 17 (13%) 7 (41%) 10 (59%)
Streptococcus spp. 9 (7%) 0 (0%) 9 (100%)
Corynebacterium spp. 13 (10%) 3 (23%) 10 (77%)
Lactobacillus spp. 17 (13%) 8 (47%) 9 (53%)
Gardnerella vaginalis 5 (4%) 2 (40%) 3 (60%)
Otherc 12 (12%) 3 (25%) 9 (75%)123
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with MUSC suVer from storage LUTS, while others remain
asymptomatic could be answered by diVerences in both
antibacterial protection mechanisms and pathogen viru-
lence. In addition, it has to be kept in mind that urinary tract
infection (UTI) and even asymptomatic bacteriuria (ASB)
are more common in women than in men. Consequently,
the rate of MUSC is higher in stents removed from women
compared with those from men [4]. Indeed, our study popu-
lation showed both a signiWcant higher rate of MUSC and
ASB in female compared with male cases. It seems to be
obvious that in accordance with the higher rate of ASB, a
major female subgroup is able to tolerate the presence of
MUSC without suVering from storage LUTS. This observa-
tion might serve as an explanation for the insigniWcant
association of MUSC and stent-related storage LUTS in
women. However, our results showed a clear trend for such
an association. In addition, the female study population
might be underpowered.
In contrast to the inconsistent relationship between
MUSC and storage LUTS, pyuria was found to be signiW-
cantly more common both in female and male patients with
storage LUTS than patients without storage LUTS. This
observation serves as a link to neurogenic inXammation
(NI), another potential aetiological factor of stent-related
storage LUTS. Pathophysiological, initial ureteral stent
activation of sensory nerves (A or C-Wbres) located in the
bladder wall leads to transmission of signals to the central
nervous system [24]. These neurons express among others,
members of the transient receptor potential (TRP) family of
ion channels, which are frequently involved in idiopathic
and neurogenic detrusor overactivity [25, 26]. Initial recep-
tor activation is followed by NI, which consists of a series
of vascular and non-vascular inXammatory responses. NI is
mediated by the release of proinXammatory neuropeptides
including substance P (SP), neurokinin A, and calcitonin
gene-related peptide (CGRP) in the periphery. These pep-
tides lead to oedema, leucocyte accumulation, formation of
radical oxygen species and promote smooth muscle con-
traction of the ureter, bladder wall and urethra [27].
The identiWcation of MUSC and NI as potential aetiologi-
cal factors of stent-related storage LUTS oVers an explanation
for the insuYcient pharmaceutical treatment of stent-related
morbidity. Although recent studies showed an improvement
of a subset of urinary symptoms by oral administration of
alpha blockers [28], the medical therapy for the majority of
patients with stent-associated storage LUTS remains unsatis-
factory. In this context, MUSC and NI should be taken into
account when developing a multimodal treatment approach
for stent-associated storage LUTS. Especially in patients
with de novo or worsened storage LUTS and accompanying
pyuria, the combination of antibiotics targeting most com-
monly isolated microorganisms with anti-inXammatory drugs
should be regarded as a treatment option. Furthermore, our
data might be useful to estimate the risk of MUSC prior to
stent manipulation which bears the risk of severe infectious
complications [29, 30].
The limitations of this study include (1) the lack of a
gold-standard deWnition of ureteral stent-related infection
and (2) the fact that the ureteral symptom questionnaire
used has not been formally validated.
Conclusions
This study demonstrates a signiWcant correlation between
MUSC and stent-related de novo or worsened storage
LUTS in men. The incidence of MUSC is most common in
male as well as in female patients with storage LUTS and
pyuria. In these patients, the combination of antibiotics and
anti-inXammatory drugs should be regarded as a treatment
option. In addition, the estimation of MUSC based on the
presence of storage LUTS and pyuria prior to stent manipu-
lation might be helpful to minimize the risk of severe post-
operative infectious complications.
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